- Home
- ULBI
as of 03-20-2026 3:36pm EST
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | NEWARK |
| Market Cap: | 97.6M | IPO Year: | 1995 |
| Target Price: | N/A | AVG Volume (30 days): | 65.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.09 | EPS Growth: | 1166.67 |
| 52 Week Low/High: | $4.07 - $9.51 | Next Earning Date: | 03-10-2026 |
| Revenue: | $164,456,000 | Revenue Growth: | 3.66% |
| Revenue Growth (this year): | 20% | Revenue Growth (next year): | N/A |
| P/E Ratio: | 74.56 | Index: | N/A |
| Free Cash Flow: | 14.7M | FCF Growth: | N/A |
AI-Powered ULBI Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ultralife Corporation (ULBI)
Director, 10% Owner
Avg Cost/Share
$6.76
Shares
53,131
Total Value
$359,112.43
Owned After
1,941,759
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$6.32
Shares
100,640
Total Value
$636,487.62
Owned After
1,941,759
SEC Form 4
President and CEO
Avg Cost/Share
$6.02
Shares
2,000
Total Value
$12,024.20
Owned After
26,674
Director, 10% Owner
Avg Cost/Share
$5.97
Shares
33,741
Total Value
$201,308.93
Owned After
1,941,759
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| WHITMORE BRADFORD T | ULBI | Director, 10% Owner | Mar 16, 2026 | Buy | $6.76 | 53,131 | $359,112.43 | 1,941,759 | |
| WHITMORE BRADFORD T | ULBI | Director, 10% Owner | Mar 13, 2026 | Buy | $6.32 | 100,640 | $636,487.62 | 1,941,759 | |
| Manna Michael Edward | ULBI | President and CEO | Mar 12, 2026 | Buy | $6.02 | 2,000 | $12,024.20 | 26,674 | |
| WHITMORE BRADFORD T | ULBI | Director, 10% Owner | Mar 12, 2026 | Buy | $5.97 | 33,741 | $201,308.93 | 1,941,759 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Mar 10, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYMar 10, 2026 · 100% conf.
1D
+2.98%
$5.97
Act: +2.97%
5D
+8.76%
$6.31
20D
+12.88%
$6.55
ulbi20260310_8k.htm
false 0000875657
0000875657
2026-03-10 2026-03-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
March 10, 2026
Date of Report (Date of Earliest Event Reported)
ULTRALIFE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 000-20852 16-1387013
(State of incorporation) (Commission File Number) (IRS Employer Identification No.)
2000 Technology Parkway, Newark, New York 14513
(Address of principal executive offices) (Zip Code)
(315) 332-7100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.10 par value per share
ULBI
NASDAQ Stock Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On March 10, 2026, Ultralife Corporation issued a press release regarding the financial results for its fourth quarter ended December 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.
Item 9.01 Financial Statements, Pro Forma Financials and Exhibits
(d) Exhibits.
Exhibit
Number
Exhibit Description
99.1
Press Release of Ultralife Corporation dated March 10, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 10, 2026
ULTRALIFE CORPORATION
By:
/s/ Philip A. Fain
Philip A. Fain
Chief Financial Officer and Treasurer
2025 Q3 Q3 2025 Earnings
8-K BUY Nov 18, 2025 · 100% conf.
Q3 2025 Earnings
8-K BUYNov 18, 2025 · 100% conf.
1D
+3.33%
$5.22
Act: +0.20%
5D
+7.83%
$5.45
Act: +16.24%
20D
+12.37%
$5.67
Act: +17.03%
ulbi20251117_8k.htm
false 0000875657
0000875657
2025-11-18 2025-11-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
November 18, 2025
Date of Report (Date of Earliest Event Reported)
ULTRALIFE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
000-20852
16-1387013
(State of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2000 Technology Parkway, Newark, New York 14513
(Address of principal executive offices) (Zip Code)
(315) 332-7100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.10 par value per share
ULBI
NASDAQ Stock Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 18, 2025, Ultralife Corporation issued a press release regarding the financial results for its third quarter ended September 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.
Item 9.01 Financial Statements, Pro Forma Financials and Exhibits
(d) Exhibits.
Exhibit
Number
Exhibit Description
99.1
Press Release of Ultralife Corporation dated November 18, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 18, 2025
ULTRALIFE CORPORATION
By:
/s/ Philip A. Fain
Philip A. Fain
Chief Financial Officer and Treasurer
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
Q2 2025 Earnings
8-KAug 7, 2025
ulbi20250806_8k.htm
false 0000875657
0000875657
2025-08-07 2025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
August 7, 2025
Date of Report (Date of Earliest Event Reported)
ULTRALIFE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
000-20852
16-1387013
(State of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
2000 Technology Parkway, Newark, New York 14513
(Address of principal executive offices) (Zip Code)
(315) 332-7100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
(Title of each class)
(Trading Symbol)
(Name of each exchange on which registered)
Common Stock, $0.10 par value per share
ULBI
NASDAQ
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 7, 2025, Ultralife Corporation issued a press release regarding the financial results for its second quarter ended June 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.
Item 9.01 Financial Statements, Pro Forma Financials and Exhibits
(d) Exhibits.
Exhibit
Number
Exhibit Description
99.1
Press Release of Ultralife Corporation dated August 7, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 7, 2025
ULTRALIFE CORPORATION
By:
/s/ Philip A. Fain
Philip A. Fain
Chief Financial Officer and Treasurer
Compare ULBI vs Leading Stocks
See how ULBI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ULBI Ultralife Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.